Comparison of Erythrocyte Sedimentation Rate and C-Reactive Protein levels between breast Cancer Patients
DOI:
https://doi.org/10.54361/ljmr.v14i2.04Keywords:
Erythrocyte Sedimentation Rate, C-Reactive Protein, Breast CancerAbstract
Background: Inflammatory response plays an essential role in the initiation and progression of several cancers, including breast cancer. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are two inflammatory indicators that increase in many pathologic and physiologic conditions. The objectives of this study were to estimate and compare the levels of these inflammatory markers in breast cancer patients with those of apparently healthy subjects without the disease. Methods: This is a case study conducted at the National Cancer Institute, Sabratha Hospital and Medical Research Center in Zawiya, during 2019. The study population includes 80 subjects (30 healthy women and 50 confirmed breast cancer cases). The levels of ESR and CRP were investigated using standardized laboratory methods. Results: The obtained results showed that the ESR levels of the participants with breast cancer were highly significant compared to that of the controls, but there was no significant difference in levels of CRP. The levels of ESR in all stages of BC were statistically significant compared to control individuals. In contrast, no significant difference in CRP in BC patients with stage III and VI and in controls, despite the significant difference in levels of CRP noticed between BC patient with stage II and controls. There were no differences between the levels of ESR in patients with and without chronic diseases. The levels of CRP showed significant differences between patients with chronic diseases and controls. ESR levels remained elevated despite the course of BC treatment and the levels of CRP in patients, who had combination of chemotherapy and radiotherapy, were increased. In conclusion, this study suggests that ESR is significantly raised in breast cancer patients, whereas, there is no association between of CRP and breast cancer
References
Mckeown N. Antioxidants and breast cancer (1999). Nutr Rev. 57: 321-324. DOI: https://doi.org/10.1023/A:1017301615564
F Balkwill, A Mantovani (2001). Inflammation and cancer: back to Virchow? Lancet. 357:539–45. DOI: https://doi.org/10.1016/S0140-6736(00)04046-0
Ganesh N. Sharma, Rahul Dave, JyotsanaSanadya, Piush Sharma, and K. K Sharma3 (2010). VARIOUS TYPES AND MANAGEMENT OF BREAST CANCER: An Overview.JAdv Pharm Technol Res. 2: 109–126.
Robert Coleman Mills (2017). Breast Cancer Survivors, Common Markers of Inflammation, and Exercise: A Narrative Review. Breast Cancer (Auckl). 11:1178223417743976. DOI: https://doi.org/10.1177/1178223417743976
Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM (2012). Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 104;815–840. DOI: https://doi.org/10.1093/jnci/djs207
Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM (2009). Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J ClinOncol. 27:3437–3444. DOI: https://doi.org/10.1200/JCO.2008.18.9068
Das Roy L, Pathangey LB, Tinder TL, Schettini JL, Gruber HE, Mukherjee P (2009). Breast‑cancer‑associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res. 11:R56. DOI: https://doi.org/10.1186/bcr2345
Mantovani A1, Garlanda C, Doni A, Bottazzi B (2007). Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J ClinImmunol. 2008 Jan;28(1):1-13. Epub
Kushner I. Acute phase reactants. UpToDate 2014 Jul 15.
Saadeh C. The erythrocyte sedimentation rate: Old and new clinical applications. South Med J 1998;91:220‑5. DOI: https://doi.org/10.1097/00007611-199803000-00001
Sox HC Jr., Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. Ann Intern Med 1986;104:515‑23 DOI: https://doi.org/10.7326/0003-4819-104-4-515
Ljungberg B, Grankvist K, Rasmuson T (1995). Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer. 76:1435‑9. DOI: https://doi.org/10.1002/1097-0142(19951015)76:8<1435::AID-CNCR2820760821>3.0.CO;2-Y
Henry‑Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, et al (1991). Erythrocyte sedimentation rate predicts early relapse and survival in early‑stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med. 114:361‑5. DOI: https://doi.org/10.7326/0003-4819-114-5-361
Mantovani A, Garlanda C, Doni A, Bottazzi B (2008). Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J ClinImmunol. 1:1-13. DOI: https://doi.org/10.1007/s10875-007-9126-7
Allin KH, Bojesen SE, Nordestgaard BG (2009). Baseline C‑reactive protein is associated with incident cancer and survival in patients with cancer. J ClinOncol. 27:2217‑24. DOI: https://doi.org/10.1200/JCO.2008.19.8440
Schmid M, Schneitter A, Hinterberger S, Seeber J, Reinthaller A, Hefler L (2007). Association of elevated C‑reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer. ObstetGynecol . 110:1231‑6. DOI: https://doi.org/10.1097/01.AOG.0000292085.50987.f2
Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A, Hefler LA (2007). C‑reactive protein is a prognostic parameter in patients with cervical cancer. GynecolOncol. 107:114‑7. DOI: https://doi.org/10.1016/j.ygyno.2007.06.001
O’Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R (2010). Elevated preoperative C‑reactive protein predicts poor cancer specific survival in patients undergoing resection for non‑small cell lung cancer. J ThoracOncol. 5:988‑92. DOI: https://doi.org/10.1097/JTO.0b013e3181da78f9
Roxburgh CS, McMillan DC (2010). Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 6:149‑63. DOI: https://doi.org/10.2217/fon.09.136
Williams MR, Turkes A, Pearson D, Griffiths K, Blamey RW (1990). An objective biochemical assessment of therapeutics response in metastatic breast, a study with external review of clinical data. Br J Cancer. 61:126-132. DOI: https://doi.org/10.1038/bjc.1990.26
ShilpaBalajiAsegaonkar, BalajiNarayanraoAsegaonkar, UnmeshVidyadharTakalkar, Suresh Advani, and AnandPandurangThorat (2015).C-Reactive Protein and Breast Cancer: New Insights from Old Molecule . Int J Breast Cancer. 26;2015:145647. DOI: https://doi.org/10.1155/2015/145647
Eboreime O, Atoe K, Idemudia JO (2015). Erythrocyte Sedimentation Rate and C-Reactive Protein Levels in Breast Cancer Patients in Benin City, Nigeria. IOSR-JDMS. 6: 116-119.
Pagana KD, Pagana TJ, MacDonald S. Mosby's Canadian manual of diagnostic and laboratory tests. Toronto: Mosby Canada; 2013.
Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC, (2006). Evaluation of an inflammation‑based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 94:227‑30. DOI: https://doi.org/10.1038/sj.bjc.6602922
Abuquerque KV, Price MR, Badley RA, Jonup I, Pearson D, Blamey RW, (1995). Pretreatment serum level of tumour makers in metastatic breast cancer; a prospective assessment of their role in predicting response to therapy and survival. Eur J SurgOncol. 24;504-9. DOI: https://doi.org/10.1016/S0748-7983(95)96935-7
Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H (1987). Interferon beta 2/B‑cell stimulatory factor type 2 shares identity with monocyte‑derived hepatocyte‑stimulating factor and regulates the major acute phase protein response in Liver Cells. ProcNatlAcadSci U S A. 20 :7251-7255. DOI: https://doi.org/10.1073/pnas.84.20.7251
Tennant F (2013). Erythrocyte sedimentation rate and C-reactive protein: old but useful biomarkers for pain treatment. Pract Pain Manage. 2:61-65
ShilpaBalajiAsegaonkar, UnmeshVidyadharTakalkar , PushpaKodlikeri , AvinashPagdhune , VirendrakumarBonduliya , AnandPandurangThorat (2014). Serum high sensitivity C-reactive protein in breast cancer patients. Int J Res Med Sci. 4:1408-1411. DOI: https://doi.org/10.5455/2320-6012.ijrms20141131
O'Hanlon,D.M., Lynch,J., Cormican,M., &Given,H.F. (2002) The acute phase response in breast carcinoma. Anticancer Res. 22, 1289-1293
University of South Australia (2018). Higher risk of chronic diseases later in life for women with breast cancer. https://www.unisa.edu.au/Media-Centre/Releases/2018/Hormone-treatment-for-breast-cancer-linked-to-chronic-disease-later-in-life/
Grace Sun, Sangeeta R Kashyap (2011). Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic Considerations. J NutrMetab. 708183. DOI: https://doi.org/10.1155/2011/708183
Jeong H, Baek S-Y, Kim SW, et al (2019). C reactive protein level as a marker for dyslipidaemia, diabetes and metabolic syndrome: results from the Korea National Health and Nutrition Examination Survey. BMJ Open;9:e029861. doi:10.1136/ bmjopen-2019-029861. DOI: https://doi.org/10.1136/bmjopen-2019-029861
Kirsten Erickson, Ruth E. Patterson, Shirley W. Flatt, Loki Natarajan, Barbara A. Parker, Dennis D. Heath,Gail A. Laughlin, NazmusSaquib, Cheryl L. Rock, and John P. Pierce (2011). Clinically Defined Type 2 Diabetes Mellitus and Prognosis in Early-Stage Breast Cancer. J ClinOncol. 1: 54–60. DOI: https://doi.org/10.1200/JCO.2010.29.3183
Mukherjee D, Coates PJ, Lorimore SA, Wright EG (2014). Responses to ionizing radiation mediated by inflammatory mechanisms. J Pathol. 3:289–99. DOI: https://doi.org/10.1002/path.4299
Hekim N, Cetin Z, Nikitaki Z, Cort A, Saygili EI (2015). Radiation triggering immune response and inflammation. Cancer Lett. 2:156–63. DOI: https://doi.org/10.1016/j.canlet.2015.04.016
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Aisha alhadimaualidi, Hayat Ali Alshamly, Amina Bshaena (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
